Predict your next investment

See what CB Insights has to offer

Investments

262

Portfolio Exits

2

About EIC Accelerator

The EIC Accelerator (previously SME Instrument) is part of the European Innovation Council (EIC) pilot that supports top-class innovators, entrepreneurs, and small companies with funding opportunities and acceleration services. The main focus of the EIC Accelerator is on market-creating innovations that shape new markets and generate jobs, growth, and higher standards of living.

EIC Accelerator Headquarter Location

Place Charles Rogier, 16

Brussels, 1210,

Belgium

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest EIC Accelerator News

Winner of the European EIC Accelerator Program, EVerZom Accelerates the Industrialization of Its Exosome Bioproduction Platform for Regenerative Medicine

Nov 18, 2021

November 18, 2021 09:00 AM Eastern Standard Time PARIS--( BUSINESS WIRE )--EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles (or exosomes), announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition. This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry. "We are delighted to be the winner of this highly selective European EIC Accelerator program, and we thank all the stakeholders involved in the European Union Horizon Europe program. This funding illustrates EVerZom's disruptive innovation in the biomanufacturing of extracellular vesicles which will provide new therapeutic modalities for tomorrow's regenerative medicine, particularly in cardiac, hepatic, and renal indications. We have just reached a key milestone which gives us good financial visibility until the end of 2022 and we expect to raise a further €3M at the end of 2022. Our ambition remains unchanged: to become the European leader in the biomanufacturing of extracellular vesicles," explains Jeanne Volatron, Co-founder and President of EVerZom. As a reminder, extracellular vesicles have the capacity to target organs or regenerate tissues in several pathologies such as osteoarthritis, to regrow tissues after a myocardial infarction or even liver and kidney diseases. Unlocking the challenge to manufacture extracellular vesicles at large scale EverZom offers a novel production process that is scalable, reproducible and has a robust quality control system. EVerZom's proprietary innovation consists in applying mechanical stimulation on the cells to trigger massive extracellular vesicles release in a reproducible, standardized manner and at large-scale. This approach allows the production of 10 times more extracellular vesicles in 10 times less time. EverZom is already marketing its biomanufacturing services to various European and US biotechs, notably for vesicular treatments of digestive fistula in patients suffering from autoimmune diseases such as Crohn's disease or in patients who have undergone bariatric surgery. About EVerZom EVerZom, a biopharmaceutical company specialized in the biomanufacturing of exosomes, is at the service of regenerative medicine with new biological tools: extracellular vesicles or exosomes, which are today considered as a safer and more practical alternative to cell-based therapies. http://everzom.com Contacts

EIC Accelerator Investments

262 Investments

EIC Accelerator has made 262 investments. Their latest investment was in Alice&Bob as part of their Seed on October 10, 2021.

CBI Logo

EIC Accelerator Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/25/2021

Seed

Alice&Bob

Yes

2

10/21/2021

Series C

VarmX

Yes

3

10/20/2021

Grant

SquareMind

Yes

2

10/19/2021

Grant

Subscribe to see more

$99M

Subscribe to see more

10

10/19/2021

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2021

10/21/2021

10/20/2021

10/19/2021

10/19/2021

Round

Seed

Series C

Grant

Grant

Grant

Company

Alice&Bob

VarmX

SquareMind

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

2

10

10

EIC Accelerator Portfolio Exits

2 Portfolio Exits

EIC Accelerator has 2 portfolio exits. Their latest portfolio exit was Metys Pharmaceuticals on September 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/7/2021

Acquired

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/7/2021

00/00/0000

Exit

Acquired

Subscribe to see more

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

2

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.